Gypenoside XLIX Ameliorate High-Fat Diet-Induced Atherosclerosis via Regulating Intestinal Microbiota, Alleviating Inflammatory Response and Restraining Oxidative Stress in ApoE−/− Mice

Ming Gao 1,2,†, Xing Heng 1,†, Jing Jin 3 and Weihua Chu 1,*†

1 State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China
2 Nanjing Zhiyi Biotechnology Co., Ltd., Nanjing 210014, China
3 The People’s Hospital of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui 323050, China
* Correspondence: chuweihua@cpu.edu.cn
† These authors contributed equally to this work.

Abstract: A high-fat choline diet (HFCD)-induced atherosclerosis model in ApoE−/− mice was established to explore the anti-atherosclerotic effects of gypenoside XLIX (GPE). It was found that HFCD-induced atherosclerotic index such as dyslipidemia, atherosclerotic plaque, inflammation, and gut microbiota dysfunction could be reduced by GPE treatment. GPE treatment could decrease Verrucomicrobia, Proteobacteria, and Actinobacteria abundance, and increase Firmicutes and Bacteroidetes population. Moreover, the Firmicutes/Bacteroidetes ratio increased significantly after treatment with GPE. After treatment with GPE, the relative abundance of trimethylamine-producing intestinal bacteria Clostridioides and Desulfovibrionaceae decreased while butyrate-producing bacteria such as Eubacterium, Roseburia, Bifidobacterium, Lactobacillus, and Prevotella increased significantly. The GPE group demonstrated higher SCFAs concentrations in the fecal sample, such as Acetic Acid, Propionic Acid, and Butyric Acid. Further pathway analysis showed that 29 metabolic pathways were appreciably disturbed during GPE treatment, including citrate cycle (TCA cycle); galactose and glycero-lipid-metabolism biosynthesis of unsaturated fatty acids, fatty acid biosynthesis. This study suggests that the anti-atherosclerotic effect of GPE is related to the substantial changes in intestinal microbiota and anti-inflammatory activity.

Keywords: atherosclerosis; gypenoside XLIX; gut microbiota; inflammation; metabolism

1. Introduction

Cardiovascular disease (CVD) is a prevalent disease which has a high mortality rate worldwide [1]. According to the WHO, cardiovascular disease includes a range of diseases which affect the health of blood vessels and heart, including angina pectoris, coronary heart disease, myocardial infarction, hypertension, congenital heart disease, heart valve disease stroke, and cardiomyopathy [2]. Atherosclerosis is one of the most common of these diseases. The feature of atherosclerosis is slow-progressing inflammation in conductance and resistance arteries, thereby causing cholesterol containing low density lipoprotein (LDL) particles which accumulate on the vascular endothelium [3]. Although the cost of medical systems in the world is rising, atherosclerosis is increasing worldwide without any available cure [4]. Atherosclerosis is influenced by multiple factors, and many studies have shown that the gut microbiota is also involved in the occurrence and development of atherosclerosis. Microbes in the gut form a vast and complex community of interacting organisms, outnumbering the total number of human cells [5]. Recent studies have shown that the gut microbiota contributes to the development of metabolic diseases, particularly...
to the target of cardiovascular diseases [6]. For example, the relative abundance of butyrate producing bacteria in the gut is significantly and negatively correlated with atherosclerosis [7]. Therefore, improving atherosclerosis by influencing the organismal pathways has drawn widespread attention [8]. There is increasing evidence that various phytochemicals can probably be protective by influencing and remodeling intestinal bacteria [9].

Traditional Chinese herbs are widely used in the clinical treatment of atherosclerosis, such as Alisma orientale (Samuel.) Juz, Salvia miltiorrhiza Bunge, Poria cocos (Schw.) Wolf, and Chuanxiong Rhizoma. Gynostemma pentaphyllum (Thunb.) Makino is an ancient Chinese herbal medicine and tea. It has effects of lowering blood pressure, blood fat and blood sugar and delaying aging. The main chemical component of Gynostemma pentaphyllum (Thunb.) Makino is gypenoside XLIX (GPE) (Figure 1). Gypenosides possessed many pharmacological activities such as anti-cancer, anti-atherogenic and neuroprotection effects, lipid-regulating effects, hepatoprotective effects, and anti-inflammation effects [10,11]. Here we hypothesized that GPE can ameliorate atherosclerosis by regulating gut microbiota and alleviating inflammation.

Figure 1. The chemical structure of gypenosides XLIX.

Apolipoproteins are the major component of circulating high-density lipoprotein (HDL) that inhibits the progression of atherosclerosis [12]. Apolipoprotein E knockout (ApoE−/−) mice is a classic model for atherosclerosis research [13]. The aim of this study is to explore the anti-atherosclerosis effect of GPE on the inflammation and intestinal microbiota in a high-fat diet and atherosclerosis induced by choline in ApoE−/− mice.

2. Results
2.1. Body Weight, Food Intake, and Organ Weight

Figure 2 is based on the record of daily food intake and body weight. It was found that, during the experiment time, there was no clear significant difference in food intake and body weight of mice among all three groups. In addition, hypertrophy was found in the livers of the GPE group despite no significant difference in liver weight.
2.2. GPE Alleviated HFCD-Induced Atherosclerotic Lesions

Mice hearts were cryo-sected to obtain the aortic root. Oil Red O was used to visualize atherosclerotic lesions of the aorta root in cross-section. The staining of the aortic sinus also showed much more severe atherosclerotic lesions in the control group. However, compared with the NOM group, atherosclerotic lesions were significantly reduced in the GPE group (Figure 3). These results showed that GPE could reduce HFCD-induced atherosclerotic lesions.

Figure 3. GPE alleviated HCD-induced atherosclerotic lesions (n = 6). (* p < 0.05, ** p < 0.01).

2.3. GPE Had Lipid-Lowering Effects

Compared with the HFCD group, we can see the levels of TC, LDL-C, and TG of GPE group, while HDL-C level was increased in GPE group (p < 0.05) (Figure 4).

Figure 2. Body weight, food intake, liver weight and shape of liver in different group of mice (n = 6). (* p < 0.05).
2.3. GPE Had Lipid-Lowering Effects

Compared with the HFCD group, we can see the levels of TC, LDL-C, and TG of GPE group, while HDL-C level was increased in GPE group ($p < 0.05$) (Figure 4).

![Figure 4](image)

**Figure 4.** GPE had lipid-lowering effects in TC, TG, LDL-C, HDL-C level ($n = 6$). (* $p < 0.05$, ** $p < 0.01$).

2.4. GPE Inhibited TMA/TMAO Metabolism

The differences in TMAO metabolism in mice treated with or without GPE were evaluated. The concentrations of TMAO in plasma in the CON group were much higher than those in the NOM group ($p < 0.01$), which means that HFCD can induce a high level of TMAO in the serum of model mice. After treatment with GPE, the concentrations of TMAO in plasma ($p < 0.01$) were reversed, which indicate that GPE can reduce the level of TMAO. On the other hand, the concentrations of FMO3 in all groups showed no significant difference (Figure 5), indicating that the changes of TMAO level in plasma would not be influenced by metabolism, and only influenced by the production of TMA by gut microbiota.

![Figure 5](image)

**Figure 5.** The concentrations of TMAO in plasma were reversed by GPE and FMO3 in all groups with no significant difference ($n = 6$). (** $p < 0.01$).

2.5. Effect of GPE Treatment on Gut Microbiota in ApoE$^{-/-}$ Mice

It was hypothesized that GPE alleviated atherosclerotic lesions and postponed the degeneration of atherosclerosis through the gut microbiota. Illumina MiSeq 16S rRNA amplicon sequencing was conducted, and Chao index, Simpson index, and Shannon index revealed that GPE treatment significantly increased the abundance of gut microbiota (Table 1). PCoA demonstrated significant variation in microbiota composition between the
CON group and the GPE group. The Venn diagrams also showed the significant changes in compositional similarity and overlaps between different groups in the OTU level. It was found that the main intestinal microbiota of the HFCD fed CON group were Firmicutes (39.362%), Verrucomicrobia (27.899%), Bacteroidetes (20.282%), Proteobacteria (9.824%), and Actinobacteria (1.841%). The main intestinal microflora of the GPE group were different from CON: Firmicutes (51.927%), Bacteroidetes (44.778%), Proteobacteria (0.963%), and Actinobacteria (0.905%). Though the Verrucomicrobia was relatively highly abundant in the CON group, it declined significantly in abundance in the GPE group and could not be called a major bacterium (Figure 6).

Table 1. α diversity analysis of gut microbiota in CON and GPE group.

|        | CON          | GPE          | p Value |
|--------|--------------|--------------|---------|
| Shannon| 3.21 ± 0.02  | 4.39 ± 0.16  | 0.01    |
| Simpson| 0.12 ± 0.03  | 0.03 ± 0.01  | 0.04    |
| Chao   | 204.30 ± 7.72| 451.03 ± 10.13| 0.01 |
| Coverage| 0.99 ± 0.00  | 0.99 ± 0.00  |         |

In addition, the abundance of Bacteroidetes and Firmicutes were paid attention to, as these bacteria account for the majority in the intestinal community of healthy people. The Firmicutes/Bacteroidetes ratio in the gut microbiota is an important health indicator, and the this increased significantly after treatment with GPE. The relative abundance of trimethylamine-producing intestinal bacteria decreased, such as Clostridioides and Desulfovibrio, while the relative abundance of other trimethylamine-producing bacteria such as Klebsiella Pneumoniae and Proteus Vulgaris did not change significantly. It was also found that bacteria which can product butyrate, such as Eubacterium, Roseburia, Bifidobacterium, Lactobacillus, and Prevotella, increased significantly after treatment with GPE (Figure 7).

2.6. In Vivo Antioxidant Capacity

The detection of oxidative stress-related enzymes in HFCD-induced atherosclerosis mice showed that activities of GSH-Px and SOD were lower in the GPE-treated group while the concentration of MDA was higher in the HFCD-induced atherosclerosis CON group compared with the NOM group. Meanwhile, compared with the HFCD-induced atherosclerosis CON group, activities of SOD and GSH-Px increased, and the concentration of MDA levels decreased when treated with GPE (Figure 8).

2.7. GPE Supplementation Reduces Inflammation in the Liver

The TNF-α, IL-6, and IL-1β mRNA expression levels were measured in the HFCD-induced atherosclerosis CON group compared with those of the NOM group, while the mRNA expression level of IL-6, IL-1β, and TNF-α decreased in the GPE treated group (p < 0.05), and some of the inflammatory cytokines reached the average level. Moreover, ICAM-1 and Ccl2 mRNA expression was elevated in the HFCD-induced atherosclerosis CON group compared with the NOM group, while the mRNA expression of those in the HFCD-induced atherosclerosis with GPE treated group decreased significantly (p < 0.05) (Figure 9).

2.8. Intestinal SCFA Metabolites

We examined the effect of GPE on core metabolite and SCFA production by gut microbes. Compared with the model group, the GPE group demonstrated higher SCFA concentrations in the fecal sample, such as Acetic Acid (2.896 mg/g vs. 5.381 mg/g, p < 0.01), Propionic Acid (0.579 mg/g vs. 1.025 mg/g, p<0.01), and Butyric Acid (0.293 mg/g vs. 1.578 mg/g, p < 0.01) (Figure 10).
Figure 6. Effect of GPE treatment on gut microbiota in ApoE<sup>−/−</sup> mice: Venn diagram analysis of unique/shared OTUs in the gut microbiota (A); Microbial community heatmap analysis (B); Major variations of the structure of the gut microbiota of mice without (C) or with (D) GPE treatment; PCA analysis (F) and uniFrac-based PCOA analysis (E); LEfSE analysis (G), respectively.
2.6. In Vivo Antioxidant Capacity

The detection of oxidative stress-related enzymes in HFCD-induced atherosclerosis mice showed that activities of GSH-Px and SOD were lower in the GPE-treated group while the concentration of MDA was higher in the HFCD-induced atherosclerosis CON group compared with the NOM group. Meanwhile, compared with the HFCD-induced atherosclerosis CON group, activities of SOD and GSH-Px increased, and the concentration of MDA levels decreased when treated with GPE (Figure 8).

2.7. GPE Supplementation Reduces Inflammation in the Liver

The TNF-α, IL-6, and IL-1β mRNA expression levels were measured in the HFCD-induced atherosclerosis CON group compared with those of the NOM group, while the mRNA expression level of IL-6, IL-1β, and TNF-α decreased in the GPE treated group (p < 0.05), and some of the inflammatory cytokines reached the average level. Moreover, ICAM-1 and Ccl2 mRNA expression was elevated in the HFCD-induced atherosclerosis CON group compared with the NOM group, while the mRNA expression of those in the HFCD-induced atherosclerosis with GPE treated group decreased significantly (p < 0.05) (Figure 9).

2.9. Significant Intestinal Metabolic Changes during GPE Intervention

After 6 weeks of treatment, the incidence of atherosclerotic lesions in the arteries and aortic sinuses of each group of mice was assessed. In the CON group of ApoE⁻/⁻ mice, atherosclerotic plaques in the aortic sinus were all significantly increased after 6 weeks of HCD treatment, whereas GPE treatment inhibited the progression of atherosclerosis. Meanwhile, the untargeted and targeted metabolomics based on GC-MS were used to obtain intestinal metabolic profiles and to identify regulators associated with the anti-atherogenic effects of GPE.
2.8. Intestinal SCFA Metabolites

We examined the effect of GPE on core metabolite and SCFA production by gut microbes. Compared with the model group, the GPE group demonstrated higher SCFA concentrations in the fecal sample, such as Acetic Acid (2.896 mg/g vs. 5.381 mg/g, \( p < 0.01 \)), Propionic Acid (0.579 mg/g vs. 1.025 mg/g, \( p < 0.01 \)), and Butyric Acid (0.293 mg/g vs. 1.578 mg/g, \( p < 0.01 \)) (Figure 10).

The PCA score plot indicated that the intestinal metabolic profiles of the normal feed group were significantly different from those of the HFCD-induced atherosclerosis CON group, and there were significant differences in the metabolic profiles of the CON and GPE groups. Then, 63 detected metabolites were identified as differential metabolites associated with the formation of atherosclerosis and effect of GPE (Table 2). This showed substantial changes in intestinal metabolites involved in amino acid metabolism, carbohydrate metabolism, tricarboxylic acid cycle, lipid metabolism and other metabolic pathways during GPE treatment. Further pathway analysis revealed that 29 metabolic pathways were disturbed to varying degrees during GPE treatment, particularly the citric acid cycle.
(TCA cycle), fatty acid biosynthesis, galactose and glycerol-lipid-metabolism biosynthesis of unsaturated fatty acids.

Table 2. Differential metabolites related to atherosclerosis in GPE treated HFCD diet group compared with HFCD diet.

| Metabolite                                      | Fold Change |
|-------------------------------------------------|-------------|
| D-Cellobiose                                    | 22.449      |
| Tyramine                                        | 13.37       |
| Melibiose                                       | 13.235      |
| Dihydro-cholesterol                             | 12.633      |
| 5-Methoxytryptamine                             | 10.771      |
| 4-O-Hexopyranosylhex-2-ulofuranose              | 9.1412      |
| D-Galacturonic acid                             | 8.8722      |
| Hydroxyproline                                  | 7.9615      |
| 3-Methyl-2-oxobutanoic acid                    | 5.8605      |
| Hexose                                          | 5.4677      |
| 3-Methyl-2-oxovalerate                          | 5.4058      |
| Oxalacetic acid                                 | 5.0682      |
| L-Phenylalanine                                 | 3.7558      |
| 3-Methyl-2-oxopentanoate                        | 3.7309      |
| 4-Methyl-2-oxopentanoate                        | 3.6265      |
| Malbit                                          | 3.5755      |
| Deoxyadenosine                                  | 3.5743      |
| Galactosyl-glycerol                             | 3.5642      |
| L-Gulcon-1,4-lactone                            | 3.2961      |
| N-Methyl-DL-alanine                             | 3.0154      |
| D-Lyxose                                        | 2.9811      |
| L-Iditol                                        | 2.9403      |
| 2-O-Methyl-D-mannopyranosa                      | 2.5005      |
| Pentose                                         | 2.4453      |
| Deoxyinosine                                    | 2.323       |
| Pantothenic acid                                | 2.1301      |
| Pseudo-uridine                                  | 2.0331      |
| Thymine                                         | 1.9163      |
| D-Tagatose                                      | 1.8483      |
| D-Glucose                                       | 1.7846      |
| 2,5,7,8-Tetramethyl-2-(5,9,13-trimethyltetradecyl)-3,4-dihydro-2h-chromen-6-ol | 1.7703 |
| Linoleate                                       | 1.7462      |
| Aldohexose                                      | 1.5223      |
| Aminomalonate                                   | 1.2711      |
| Di-isopropanolamine                             | 1.268       |
| Glycerol                                        | 0.6751      |
| Hexa-decanoic acid                              | 0.6641      |
| Propane-1,3-diol                                | 0.66263     |
| Lactic acid                                     | 0.66201     |
| gamma-Aminobutyric acid                         | 0.59821     |
| L-Alanyl-L-alanine                              | 0.53075     |
| Glycolic acid                                   | 0.52183     |
| Octadecanoic acid                              | 0.51757     |
| Malic acid                                      | 0.46053     |
| Chimyl alcohol                                  | 0.41685     |
| 4-Hydroxyphenyllactic acid                      | 0.38248     |
| Cholesterol                                     | 0.3759      |
| Batyl alcohol                                   | 0.37026     |
| 2,3-Bisphospho-glyceric acid                   | 0.29243     |
| Creatine                                        | 0.28688     |
| 2,3-Diaminopropionic acid                       | 0.26765     |
Table 2. Cont.

| Metabolite                                      | Fold Change  |
|------------------------------------------------|--------------|
| 3-Epicholic acid                               | 0.19065      |
| Icosanoic acid                                 | 0.18807      |
| 11beta-Hydroxyandrostenedione                  | 0.15335      |
| 4-Hydroxyphenylacetic acid                     | 0.14495      |
| 1-Eicosanol                                    | 0.13899      |
| Butenedioic acid                               | 0.11864      |
| 2-Deoxy-D-galactose                            | 0.11572      |
| L-Aspartate                                    | 0.097594     |
| Octadecanol                                    | 0.070298     |
| 3,4-Dihydroxyphenylacetic acid                 | 0.028664     |
| Cholan-24-oic acid, 3,7,12-trihydroxy-,        | 0.0058382    |
| (3alpha,5beta,7alpha,12alpha)-                |              |
| Cholic acid                                    | 0.0040922    |

3. Discussion

Knowledge of the role of microbes in human health and disease is growing. The different compounds influencing gut microbes probably play an important role in human health. Although research in “the microbiome as drug” is still in its infancy, drug discovery in the field of the microbiome has enormous untapped potential. The results suggest that the possible reason for GPE attenuating atherosclerotic lesions significantly and delaying the progression of atherosclerosis is the effect of GPE on the gut microbiota of ApoE−/− mice. As a key factor in atherosclerosis, the maladaptive inflammatory response to subcuticular lipoproteins leads to the failure of inflammation resolution, promoting the transformation of the atherosclerotic lesion into a more severe plaque [14].

Relevant studies have shown that there is dyslipidemia in atherosclerosis which is characterized by increased LDL-C and TG and decreased HDL-C, indicating that atherosclerotic mice had higher TG, TC and LDL-C levels and lower HDL-C levels [15]. Increased serum LDL-C levels are widely recognized as an important manifestation that promotes the risk of endothelial dysfunction and the progression of atherosclerosis [16]. After gavage treatment of mice with GPE, the levels of the above indicators were reversed to varying degrees. The increased TC and LDL-C contributed to the development of atherosclerosis. Moreover, the low level of HDL-C is correlated with an enhanced risk of cardiovascular disease.

According to reports, the oxidative stress caused by disruption of the balance between antioxidants and reactive oxygen radicals, which included excessive production of reactive oxygen species and reduction of antioxidant activity in the body, has been implicated in the progression of several CVD, including atherosclerosis [17]. Oxidative damage in HFCD-induced ApoE−/− mice decreased after GPE treatment, with increased SOD and GSH-Px, and decreased MDA. The two antioxidant enzymes with high efficiency, SOD and GSH-Px, could convert highly reactive free radicals into less reactive ones. Thus, the formation of water and molecular oxygen or the conjugation with harmful compounds was prevented, and safer substances were produced instead of toxic [18]. In particular, this can prevent lipid peroxidation and reduce the risk of atherosclerosis.

In atherosclerosis, elevated expression of ICAM-1, VCAM-1, and selectins are essential markers of endothelial dysfunction. ICAM-1 is involved in atherosclerosis development by regulating the adhesion of inflammatory cells such as monocytes to endothelial cells and their entry into the sub-endothelium. Several stimuli such as LDL, TNF-α, and high glucose can upregulate ICAM-1 expression in endothelial cells and increase monocyte-endothelial cell adhesion [19]. In addition, it has been proved that inflammation drives the formation, development and rupture of atherosclerotic plaques, and the proinflammatory factors are produced by the inflammatory subset of monocytes or the accumulation of macrophages [20]. In this study, atherosclerotic plaque area of aorta in GPE group decreased. Furthermore, the expression of inflammatory cytokines TNF-α and IL-6 were decreased.
The increased inflammation cytokines, including IL-6, IL-1β, and TNF-α, are also the main characteristics of atherosclerosis [21].

*Staphylococcus*, *Klebsiella pneumoniae*, *Streptococcus*, and *Proteus vulgaris* have been found in both atherosclerotic lesions and intestinal tract of the same individual. This finding suggests that the intestinal microbiota is involved in the formation and development of atherosclerosis [22]. It has been found that atherosclerotic patients show a relative reduction in *Prevotella* and *Bacteroides*, but increasing in *Escherichia* and *Streptococcus* [23]. Similar findings in this study had an average enrichment of *Prevotella* in the gut when atherosclerosis symptoms began to resolve and a decrease of *Streptococcus* and *Escherichia*. However, patients in Poland with abnormal cholesterol concentration and LDL-C levels have rich *Prevotella*, low *Clostridium* and *Faecalibacterium* proportion [24]. The relative depletion of butyrate producing bacteria (Roseburia and Eubacteria) was negatively correlated with the development of atherosclerotic lesions in patients and genetic mouse models [25]. Therefore, the changes in the various butyrate-producing bacteria were investigated. The relative consumption of *Roseburia* and *Eubacterium* can produce butyrate, which is inversely correlated with the development of atherosclerotic lesions in patients and genetic mice models [26]. Previous studies have shown that the increase in TMAO levels may be related to the increase in the proportion of Firmicutes or the decrease of *Bacteroides* proportion [27]. However, it is not clear which species play a dominant role in the formation of atherosclerosis [28]. The mechanism of how the gut microbiota affects the development of atherosclerosis is an important topic for future research.

In depth analysis of the gut microbiota revealed that trimethylamine lyase secreted by gut bacteria was affected, thereby affecting the process of choline conversion to TMA, resulting in a decrease in TMAO levels. According to non-targeted metabolomics analysis, metabolic pathways were significantly disturbed, including citrate cycle (TCA cycle), galactose and glycerolipid metabolism biosynthesis of unsaturated fatty acids; fatty acid biosynthesis. TCA is the center of carbohydrate, protein and lipid metabolism in the body. In particular, acetyl-CoA from citric acid, an intermediate product of the TCA cycle, are essential for lipid biosynthesis, which contributes significantly to lipid storage in mammals [29]. Thus, certain effects on lipid metabolism occur when there are changes in TCA-related enzymes. Choline-TMA-TMAO metabolic pathway interacts with lipid metabolism; changes in body lipid metabolism can affect the choline-TMA-TMAO pathway, while choline metabolism, based on gut microbiota, can influence metabolic function in many ways. [30,31]. How much of the gut metabolic pathways change affect the development of atherosclerosis is also a major topic for future research.

Through this animal experimental study, we found that gypenoside XLIX can alleviate atherosclerosis by regulating the intestinal microbiota, inhibiting trimethylamine production, alleviating inflammatory response and restraining oxidative stress. However, whether it is effective in clinical practice is worth further study. In the future, we will study the anti-atherosclerosis effect of gypenoside XLIX in combination with clinical practice.

4. Materials and Methods
4.1. Reagents

Gypenoside XLIX (GPE) was purchased from Wuhan Weiss Biological Engineering Co., Ltd. (Wuhan, China) (purity >98%). Choline was purchased from Shanghai Macklin Biochemical Technology Co., Ltd. (Shanghai, China).

4.2. Ethics Statement

In this research, the use of mice was approved by the China Pharmaceutical University Animal Care and Use Committee (20210412) and all experimental animal procedures followed the guidelines of the Institute Animal Care and Use Committee of China Pharmaceutical University.
4.3. Animal and Choline Treatment

After one-week acclimatization, 24 ApoE\(^{-/-}\) mice were divided into 3 groups randomly: NOM group (normal feed group: regular diet, physiological saline by gavage), CON group (HFCD diet, physiological saline by gavage), and GPE group (HFCD diet with 30 mg kg\(^{-1}\) d\(^{-1}\) GPE by gavage). The regular commercial mice feeds contained 6.2% fat, 35.6% carbohydrate, 20.8% protein, and the calorific value: 17.6 KJ/g. The HFCD mice feeds contained 0.15% cholesterol, 21% fat, and 1% choline chloride. The NOM group was set up to observe the physiological indexes of normal mice. Changing the water and treatments were processed daily for 6 weeks.

In the end, mice were anesthetized with 50 mg/kg by gavage secobarbital. Blood was collected from orbital veins, and serum were separated from whole blood by centrifugation (2500 rpm for 15 min at 4 °C) and stored at −80 °C immediately. Moreover, the heart tissues, liver tissues and whole aorta were taken.

4.4. Biochemical Analysis

The levels of triglyceride (TG) and total cholesterol (TC) in the liver, TG, TC, high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) in serum were determined using commercial ELISA kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer’s instructions.

4.5. Analysis of Atherosclerotic Lesions

After collecting blood samples, the circulatory system was flushed using a stroke-physiological saline solution. Heart and aortic tissue from the aortic root to the iliac bifurcation were taken and stored in 4% paraformaldehyde for 6 h, frozen in liquid nitrogen and cut into 5 mm sections, then subjected to Oil Red O staining to analyze atherosclerotic lesions. The percentage of atherosclerotic lesion area shown by oil red O staining represents the relative severity of atherosclerosis. The area and size of the lesions were quantified by Image J.

4.6. Detection of FMO3 and TMAO in Mice

Since FMO3 in the liver was important to TMA/TMAO cycling, the protein expression of FMO3 was detected by an enzyme-linked immunosorbent assay according to the manufacturer’s protocol (Shanghai Jining Shiye, Shanghai, China). Briefly, mouse liver was homogenized (1.0 g of liver sample in 10 mL ice cold 0.9% NaCl solution), and then centrifuged at 3000 rpm for 10 min at 4 °C, and the supernatant was used to determine the content of FMO3. The concentrations of TMAO in plasma were then assessed by the ELISA method according to the manufacturer’s protocol (Shanghai Jining Shiye, Shanghai, China).

4.7. The Effect of GPE on Gut Microbiota

The V3-V4 region of the bacterial 16S rRNA gene was amplified with extracted DNA as a template using the Applied Biosystems PCR system (GeneAmp® 9700, ABI, Foster City, CA, USA). The amplified products were then purified by TIAGEN DNA gel purification kit (TIAGEN Mini Purification Kit, TIAGEN, Beijing, China). MiSeq library construction and sequencing were performed and bioinformation analyzed as described by Segata et al. [32].

4.8. In Vivo Antioxidant Capacity of GPE

Glutathione peroxidase (GSH-Px) in the liver, malondialdehyde (MDA), and superoxide dismutase (SOD) in serum were determined with the commercial test kits (Nanjing Jiancheng Institute of Biological Engineering) following the manufacturer’s instructions to show the effect of antioxidants in vivo.

4.9. RNA Isolation and Real-Time PCR

Total RNA was extracted from liver tissues of the NOM, CON and GPE groups using Trizol reagent (Thermo Fisher, Waltham, MA, USA). The concentration and integrity of
extracted RNA were detected by Nanodrop 2000 and PCR analyze, respectively. The RNA was reverse transcribed to cDNA using PrimeScript™ RT reagent Kit (TaKaRa, Japan). ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) was used to conduct Real-time PCR. The relative expression of every target gene was normalized and the relative expression data were analyzed using the $2^{-\Delta\Delta Ct}$ method. The primer sequences of detected genes are listed in Table 3.

Table 3. PCR gene specific primer pairs.

| Gene   | Primer Sequence (5'-3') |
|--------|-------------------------|
| IL-1β  | FOR: GGTCAAAGGTTTGGAAAGCAG<br>REV: TGTGAATGCCACCTTTTTGA<br>FOR: AGGGTCTGGGCCATAGAAT<br>REV: CCACCACCGCTCTTCGTCTAC<br>FOR: AGGGTCTGGGCCATAGAAT<br>REV: CCACCACCGCTCTTCGTCTAC<br>FOR: AACAGTTCACCTGCACGGAC<br>REV: GTCACCGTTGTGATCCCTG<br>FOR: ATTGGGATCATCTTGCTGGT<br>REV: CCTGCTGTTCACAGTTGCC<br>FOR: GCTGTGCTATGTTGCTCTAG<br>REV: CGCTCGTGTGCAATAGTG |

4.10. SCFA Analysis by HSGC/MS

SCFA analysis was accomplished by Agilent 7890 gas chromatograph (Agilent Corporation, Santa Clara, CA, USA) coupled with a 5975c inert MSD quadrupole mass spectrometer, and a DB-FFAP capillary column (30 mm × 0.25 mm i.d., 0.25 mm film thickness). 0.1 g of homogenized fecal sample was mixed with 1 mL of 6% H₃PO₄ solution and ultrasonic for 3 min, then placed in a headspace autosampler at 80 °C for 30 min. Subsequently, 1 mL samples were injected into the column at 80 °C. Helium gas was used as a carrier for the sample and passed through the column at a constant flow rate of 1 mL/min. The oven was preheated at 50 °C for 1 min, then heated up 10 °C/min to 200 °C. The temperature of ion source was 250 °C and temperature of syringe also was 250 °C. With ionization energy of 70 eV, the mass detector system was operated in EI mode. The monitored ion data were collected between m/z 33 to 200. Short chain fatty acids were quantified by the mass spectrometry Library of the National Institute of Standards and Technology.

4.11. GC-TOF-MS-Based Metabolomics Analyses

Based on the methods of Yang et al. [33] and Wen et al. [34], metabolomics analyses were performed by gas chromatography. DB-5MS capillary column (30 m × 0.25 mm i.d., 0.25 μm film thickness, Agilent J & W Scientific, Folsom, CA, USA) was used to separate the derivatives.

4.12. Statistical Analysis

Differences between the two groups were assessed using the t-test, while differences between multiple groups were compared using one-way analysis of variance (ANOVA). Data were analyzed using the Statistical Package for the Social Sciences (SPSS) 26.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 8 was used for graphics. $p < 0.05$ was considered to be a statistically significant difference.

5. Conclusions

Gynostemma pentaphyllum is frequently prescribed to treat cardiovascular diseases in China. In this study, we found that gypenoside XLIX can reduce atherosclerosis and the anti-atherosclerotic effect of GPE is related to the substantial changes in intestinal microbiota and anti-inflammatory activity. This can provide a certain theoretical basis for the treatment of atherosclerosis with Chinese herbal medicine.
Author Contributions: W.C. conceived and designed the experiment. X.H., M.G. and J.J. performed the experiments. X.H. handled the data analysis. X.H. and W.C. wrote the paper. X.H., J.J. and M.G. handled the article revision. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) and the Key Discipline Project of Lishui City, Zhejiang Province, China (2021GYX21).

Institutional Review Board Statement: The animal study protocol was approved by the Institutional Review Board of China Pharmaceutical University Animal Care and Use Committee (protocol code 20210412 and 12 April 2021).

Informed Consent Statement: Not applicable.

Data Availability Statement: The raw data for 16S rRNA gene sequence have been deposited in the NCBI BioProject database ([https://www.ncbi.nlm.nih.gov/bioproject/](https://www.ncbi.nlm.nih.gov/bioproject/), 10 February 2022) under accession number: PRJNA769542. The other data of this study are available on request from W.C.

Acknowledgments: We thank to Biomarker Technologies Corporation for helping to establish the procedures for library preparation and Illumina sequencing and Suzhou BioNovoGene Metabolomics Platform for the assistance in metabolomics analyses.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sandoval-Gallegos, E.M.; Ramírez-Moreno, E.; Lucio, J.D.; Arias-Rico, J.; Cruz-Cansino, N.; Ortiz, M.I.; Carió-Cortés, R. In Vitro Bioaccessibility and Effect of Mangifera indica (Ataulfo) Leaf Extract on Induced Dyslipidemia. *J. Med. Food* 2018, 21, 47–56. [CrossRef] [PubMed]

2. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The Impact of the Gut Microbiota on Human Health: An Integrative View. *Cell* 2012, 148, 1258–1270. [CrossRef] [PubMed]

3. Lusis, A.J. Atherosclerosis. *Nature* 2000, 407, 233–241. [CrossRef] [PubMed]

4. Albany, C.J.; Trevelin, S.C.; Giganti, G.; Lombardi, G.; Scottà, C. Getting to the Heart of the Matter: The Role of Regulatory T-Cells (Treg) in Cardiovascular Disease (CVD) and Atherosclerosis. *Front. Immunol.* 2019, 10, 2795. [CrossRef]

5. Aziz, Q.; Doré, J.; Emmanuel, A.; Guarnier, F.; Quigley, E.M.M. Gut microbiota and gastrointestinal health: Current concepts and future directions. *Neurogastroenterol. Motil.* 2013, 25, 4–15. [CrossRef]

6. Heintz-Buschart, A.; Wilmes, P. Human Gut Microbiome: Function Matters. *Trends Microbiol.* 2018, 26, 563–574. [CrossRef]

7. Kasahara, K.; Krautkramer, K.A.; Org, E.; Romano, K.A.; Kerby, R.L.; Vivas, E.I.; Mehrabian, M.; Denu, J.M.; Bäckhed, F.; Lusis, A.J. Interactions Between Roseburia Intestinalis and Diet Modulate Atherogenesis in a Murine Model. *Nat. Microbiol.* 2018, 3, 1461–1471. [CrossRef]

8. Loscalzo, J. Gut Microbiota, the Genome, and Diet in Atherogenesis. *N. Engl. J. Med.* 2013, 368, 1647–1649. [CrossRef]

9. Lee, H.-S.; Kim, M.-J. Selective Responses of Three Ginkgo biloba Leaf-Derived Constituents on Human Intestinal Bacteria. *J. Agric. Food Chem.* 2002, 50, 1840–1844. [CrossRef]

10. Su, C.; Li, N.; Ren, R.; Wang, Y.; Su, X.; Lu, F.; Zong, R.; Yang, L.; Ma, X. Progress in the Medicinal Value, Bioactive Compounds, and Pharmacological Activities of *Gynostemma* Pentaphyllum. *Molecules* 2021, 26, 6249. [CrossRef]

11. Li, K.; Ma, C.; Li, H.; Dev, S.; He, J.; Qu, X. Medicinal Value and Potential Therapeutic Mechanisms of *Gynostemma* pentaphyllum (Thunb.) Makino and Its Derivatives: An Overview. *Curr. Top. Med. Chem.* 2020, 19, 2855–2867. [CrossRef] [PubMed]

12. Davidson, W.S.; Thompson, T. The Structure of Apolipoprotein A-I in High Density Lipoproteins. *J. Biol. Chem.* 2007, 282, 22249–22253. [CrossRef]

13. Ohashi, R.; Mu, H.; Yao, Q.; Chen, C. Cellular and Molecular Mechanisms of Atherosclerosis with Mouse Models. *Trends Cardiovasc. Med.* 2004, 14, 187–190. [CrossRef] [PubMed]

14. Tabas, I. Macrophage Death and Defective Inflammation Resolution in Atherosclerosis. *Nat. Rev. Immunol.* 2009, 10, 36–46. [CrossRef] [PubMed]

15. Mulvihill, E.E.; Assini, J.M.; Sutherland, B.G.; DiMattia, A.S.; Khami, M.; Koppes, J.B.; Sawyce, C.G.; Whitman, S.C.; Huff, M.W. Naringenin Decreases Progression of Atherosclerosis by Improving Dyslipidemia in High-Fat–Fed Low-Density Lipoprotein Receptor–Null Mice. *Arter. Thromb. Vasc. Biol.* 2010, 30, 742–748. [CrossRef] [PubMed]

16. Chanet, A.; Milenkovic, D.; Deval, C.; Potier, M.; Constans, J.; Mazur, A.; Bennetau-Pelissier, C.; Morand, C.; Bérard, A.M. Naringin, the Major Grapefruit Flavonoid, Specifically Affects Atherosclerosis Development in Diet-Induced Hypercholesterolemia in Mice. *J. Nutr. Biochem.* 2011, 23, 469–477. [CrossRef]

17. Pettersson, K.; Björk, H. Inhibition of Platelet Accumulation By B1-Adrenoceptor Blockade in the Thoracic Aorta of Rabbits Subjected to Experimental Sympathetic Activation. *Cardiovasc. Drugs Ther.* 1992, 6, 505–511. [CrossRef]
18. Goc, Z.; Szaroma, W.; Kapusta, E.; Dziubek, K. Protective Effects of Melatonin on the Activity of SOD, CAT, GSH-Px and GSH Content in Organs of Mice after Administration of SNP. *Chin. J. Physiol.* 2017, 60, 1–10. [CrossRef]
19. Wang, J.; Zhang, Y.; Yang, C.; Hou, M.; Wang, F.; Wang, G.; Wang, S. Effect of Tectorigenin on MCP-1 and ICAM-1 mRNA Expression in Injured Vascular Endothelial Cells. *Zhongguo Zhong Yao Za Zhi = Zhonggao Zhongyao Zazhi = China J. Chin. Mater. Med.* 2010, 35, 2001–2003.
20. Libby, P.; Okamoto, Y.; Rocha, V.Z.; Folco, E. Inflammation in Atherosclerosis: Transition from Theory to Practice. *Circ. J.* 2010, 74, 213–220. [CrossRef]
21. Ott, S.J.; El Mokhtari, N.E.; Musfeldt, M.; Hellmig, S.; Freitag, S.; Rehman, A.; Kühlbacher, T.; Nikolaus, S.; Namsolleck, P.; Blaut, M.; et al. Detection of Diverse Bacterial Signatures in Atherosclerotic Lesions of Patients with Coronary Heart Disease. *Circulation* 2006, 113, 929–937. [PubMed]
22. Di Pietro, M.; Filardo, S.; De Santis, F.; Sessa, R. Chlamydia Pneumoniae Infection in Atherosclerotic Lesion Development Through Oxidative Stress: A Brief Overview. *Int. J. Mol. Sci.* 2013, 14, 15105–15120. [CrossRef] [PubMed]
23. Jie, Z.; Xia, H.; Zhong, S.-L.; Feng, Q.; Li, S.; Liang, S.; Zhong, H.; Liu, Z.; Gao, Y.; Zhao, H.; et al. The Gut Microbiome in Atherosclerotic Cardiovascular Disease. *Nat. Commun.* 2017, 8, 845. [CrossRef] [PubMed]
24. Karlsson, F.; Fåk, F.; Nookaew, I.; Tremaroli, V.; Fagerberg, B.; Petranovic, D.; Bäckhed, F.; Nielsen, J. Symptomatic Atherosclerosis is Associated with an Altered Gut Microbiome. *Nat. Commun.* 2012, 3, 1245. [CrossRef] [PubMed]
25. Hui, D.Y. Intestinal Phospholipid and Lysophospholipid Metabolism in Cardiometabolic Disease. *Curr. Opin. Lipidol.* 2016, 27, 507–512. [CrossRef]
26. Jin, L.; Shi, X.; Yang, J.; Zhao, Y.; Xue, L.; Xu, L.; Cai, J. Gut Microbes in Cardiovascular Diseases and Their Potential Therapeutic Applications. *Protein Cell* 2021, 12, 346–359. [CrossRef]
27. Anselmi, G.; Gagliardi, L.; Egidi, G.; Leone, S.; Gasbarrini, A.; Miggiano, G.A.D.; Galiuto, L. Gut Microbiota and Cardiovascular Diseases: A Critical Review. *Cardiol. Rev.* 2021, 29, 195–204. [CrossRef]
28. Mullen, A.R.; Wheaton, W.W.; Jin, E.S.; Chen, P.-H.; Sullivan, L.B.; Cheng, T.; Yang, Y.; Linehan, W.M.; Chandel, N.S.; DeBerardinis, R.J. Reductive Carboxylation Supports Growth in Tumour Cells with Defective Mitochondria. *Nature* 2011, 481, 385–388. [CrossRef] [PubMed]
29. Heyse, M.; Schneider, C.; Monostori, P.; Schwarz, K.V.; Hauke, J.; Drüschler, K.; Berberich, A.; Zorn, M.; Ringleb, P.A.; Okun, J.G.; et al. Trimethylamine-N-Oxide Levels Are Similar in Asymptomatic vs. Symptomatic Cerebrovascular Atherosclerosis. *Front. Neurol.* 2021, 12, 617944. [CrossRef] [PubMed]
30. Cho, C.E.; Taesuwan, S.; Malyshova, O.V.; Bender, E.; Tulchinsky, N.F.; Yan, J.; Sutter, J.L.; Caudill, M.A. Trimethylamine-N-Oxide (TMAO) Response to Animal Source Foods Varies Among Healthy Young Men and Is Influenced by Their Gut Microbiota Composition: A Randomized Controlled Trial. *Mol. Nutr. Food Res.* 2017, 61, 1600324. [CrossRef]
31. Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y.; et al. TCMSP: A Database of Systems Pharmacology for Drug Discovery from Herbal Medicines. *J. Cheminform.* 2014, 6, 13. [CrossRef] [PubMed]
32.SEGATA, N.; Izard, J.; Waldron, L.; Gevers, D.; Miropolsky, L.; Garrett, W.S.; Huttenhower, C. Metagenomic Biomarker Discovery and Explanation. *Genome Biol.* 2011, 12, R60. [CrossRef] [PubMed]
33. Yang, C.; Hao, R.; Du, X.; Wang, Q.; Deng, Y.; Sun, R.; Zheng, Z. GC–TOF/MS-Based Metabolomics Studies on the Effect of Protein Sources in Formulated Diet for Pearl Oyster Pinctada Martensii. *Aquaculture* 2018, 486, 139–147. [CrossRef]
34. Wen, B.; Jin, S.R.; Chen, Z.Z.; Gao, J.Z. Physiological Responses to Cold Stress in the Gill of Discus Fish (Symphysodon Aequifasciatus) Revealed by Conventional Biochemical Assays and Ge-Tof-Ms Metabolomics. *Sci. Total Environ.* 2018, 640, 1372–1381. [CrossRef] [PubMed]